{"id":"NCT00772031","sponsor":"Anne Lindblad","briefTitle":"NINDS CRC Chronic Migraine Treatment Trial","officialTitle":"NINDS Clinical Research Collaboration Chronic Migraine Treatment Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2008-10-15","resultsPosted":"2012-01-19","lastUpdate":"2012-01-24"},"enrollment":191,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Chronic Migraine"],"interventions":[{"type":"DRUG","name":"propranolol LA","otherNames":["Inderal LA"]},{"type":"DRUG","name":"topiramate","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the reduction in the number of severe headache days at six months in people with chronic migraine treated with topiramate and propranolol versus those treated with topiramate and a placebo.","primaryOutcome":{"measure":"Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline","timeFrame":"Baseline (pre-randomization), months 5 and 6 post randomization","effectByArm":[{"arm":"Topiramate Plus Propranolol","deltaMin":4.4,"sd":5.98},{"arm":"Topiramate Plus Placebo","deltaMin":4.7,"sd":5.66}],"pValues":[{"comp":"OG000 vs OG001","p":"0.77"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":39,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":96},"commonTop":["Fatigue","Paraesthesia","Mental Impairment","Dizziness","Memory Impairment"]}}